CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-24 | Marriott Tina President and COO | Sale 10b5-1 | −6,000 | $6.31 | $38K | 521,138 |
| 2024-10-24 | Marriott Tina President and COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −6,000 | 452,000 | ||
| 2024-10-15 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $6.67 | $76K | 7,089,007 |
| 2024-10-09 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +39,375 | $2.22 | $87K | 1,465,881 |
| 2024-10-09 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −15,000 | $6.36 | $95K | 1,450,881 |
| 2024-10-09 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −39,375 | 416,385 | ||
| 2024-10-08 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +39,375 | $2.22 | $87K | 1,441,506 |
| 2024-10-08 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −15,000 | $6.32 | $95K | 1,426,506 |
| 2024-10-08 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −39,375 | 455,760 | ||
| 2024-10-03 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 782,656 | ||
| 2024-10-03 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $6.08 | $122K | 762,656 |
| 2024-10-03 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 6,096,700 | ||
| 2024-10-02 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 782,656 | ||
| 2024-10-02 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $6.16 | $123K | 762,656 |
| 2024-10-02 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 6,116,700 | ||
| 2024-10-01 | Borgeson Blake Director | Grant or award | +2,026 | 7,100,454 | ||
| 2024-10-01 | Dar Zavain Director | Grant or award | +2,229 | 106,225 | ||
| 2024-10-01 | Li Dean Y Director | Grant or award | +1,925 | 75,703 | ||
| 2024-10-01 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $6.22 | $71K | 7,098,428 |
| 2024-09-26 | Marriott Tina President and COO | Exercise or conversion 10b5-1 | +6,000 | $1.06 | $6K | 527,138 |
Page 14 of 41 · 805 trades